NCT06069726 (MOAB) is a Phase 2 clinical trial of Atezolizumab in Recurrent Glioblastoma, sponsored by Duke University.

Who is sponsoring NCT06069726?

NCT06069726 is sponsored by Duke University.

What drugs are being tested in NCT06069726?

Interventions in NCT06069726: Atezolizumab.

What condition does NCT06069726 study?

NCT06069726 studies Recurrent Glioblastoma.

Is NCT06069726 still recruiting?

NCT06069726 is currently recruiting now. Last updated 31 October 2025.

Last reviewed 2025-10-31 · How we verify

NCT06069726: MOAB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Recruiting now Phase 2 Last updated 31 October 2025

What this trial tests

Phase 2 trial testing Atezolizumab in Recurrent Glioblastoma in 80 participants. Currently enrolling.

Timeline

21 March 2024

Primary endpoint
1 January 2028

1 January 2028

Quick facts

Lead sponsor	Duke University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	21 March 2024
Primary completion	1 January 2028
Estimated completion	1 January 2028
Sites	4 locations across United States

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →

Sponsor

Duke University

Who can join

18 and older, any sex, with Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
Salvato I, Marchini A. · · 2024 · cited 32× · PMID 38610954 · DOI 10.3390/cancers16071276
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
Badani A, Ozair A, Khasraw M, Woodworth GF, et al · · 2025 · cited 12× · PMID 39570554 · DOI 10.1007/s11060-024-04881-2
Barriers to T Cell Functionality in the Glioblastoma Microenvironment.
Nader NE, Frederico SC, Miller T, Huq S, et al · · 2024 · cited 8× · PMID 39409893 · DOI 10.3390/cancers16193273
Role of Podoplanin (PDPN) in Advancing the Progression and Metastasis of Glioblastoma Multiforme (GBM).
Sharma B, Agriantonis G, Shafaee Z, Twelker K, et al · · 2024 · cited 4× · PMID 39682237 · DOI 10.3390/cancers16234051
Emerging insights into the immunosuppressive tumor microenvironment and its implications for glioblastoma immunotherapy.
Nicolaou N, Andreou MS, Neophytou CM, Papageorgis P. · · 2025 · cited 2× · PMID 41208963 · DOI 10.3389/fimmu.2025.1665742
The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.
van Opijnen MP, de Vos FYF, Cuppen E, Geurts M, et al · · 2024 · cited 2× · PMID 39316248 · DOI 10.1007/s12032-024-02501-7
Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies.
Cao Z, Tong S, Wang Z, Ji C, et al · · 2026 · PMID 41809120 · DOI 10.2147/itt.s581012

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Recurrent Glioblastoma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06069726 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 31 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06069726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing